New capabilities strengthen U.S. production, completing Moderna’s domestic end-to-end mRNA manufacturing network More than $140 million investment will create hundreds of highly skilled ...

Moderna has announced a $140 million investment to enhance its Massachusetts manufacturing capacity, a move that supports ...

With much of Moderna’s recent rise tied to its COVID-19 vaccine, the company has struggled to match the sales highs it ...

With much of Moderna’s rise in this decade tied to its COVID-19 vaccine, the company has struggled in recent years to match ...

A Centers for Disease Control and Prevention webpage that previously stated "Vaccines do not cause autism" has been changed ...

At an analyst day event, Moderna said it wants to invest revenue from a hopefully expanded seasonal vaccine franchise into ...

Shares of Moderna are falling Thursday. The company made two significant announcements regarding its finances and business ...

Pfizer has released the full data from its phase 3 trial of an mRNA flu vaccine candidate, with the potential new shot demonstrating 34.5% greater efficacy compared to a control vaccine. | Pfizer has ...

Moderna (NASDAQ:MRNA) gained 3% on Thursday after presenting a new multi-year roadmap at its Analyst Day, detailing how it ...

Malone, known for promoting disputed claims about COVID vaccines, will serve in an unpaid role focused on federal policy ...

Lots more details about the fallout from STAT’s John Wilkerson. Read more here.

Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox.